FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy

What's new in pharma

July 18, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kristoffer Tripplaar/Sipa via AP STAT+ | Sarepta Therapeutics crisis is huge blow to Duchenne families, company Following a string of patient deaths, the FDA may pull the company's gene therapy from the market, at least temporarily. By Jason Mast and Adam Feuerstein Inside an FDA drug rejection, and layoffs at Sarepta This week, we discuss why the Food and Drug Administration rejected Ultragenyx's rare disease drug over manufacturing qualms. By Allison DeAngelis, Adam Feuerstein, and Elaine Chen Opinion: Medicaid cuts will further strain free and charitable health clinics Despite growing demand — driven in part by rising living costs — free and charitable clinics operate under increasing financial strain. By Ariana Gordillo De Vivero and Harley Jones Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser